Blue Fin Capital Inc. Has $2.87 Million Position in Stryker Co. (NYSE:SYK)

Blue Fin Capital Inc. lifted its holdings in shares of Stryker Co. (NYSE:SYK) by 2.0% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 9,598 shares of the medical technology company’s stock after buying an additional 185 shares during the period. Blue Fin Capital Inc.’s holdings in Stryker were worth $2,874,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the business. Vanguard Group Inc. boosted its position in Stryker by 0.5% during the third quarter. Vanguard Group Inc. now owns 30,665,520 shares of the medical technology company’s stock valued at $8,379,967,000 after purchasing an additional 143,631 shares during the last quarter. FMR LLC grew its stake in shares of Stryker by 2.5% in the third quarter. FMR LLC now owns 5,972,582 shares of the medical technology company’s stock valued at $1,632,127,000 after buying an additional 144,208 shares in the last quarter. Morgan Stanley increased its holdings in Stryker by 4.4% during the third quarter. Morgan Stanley now owns 5,315,227 shares of the medical technology company’s stock worth $1,452,493,000 after buying an additional 223,728 shares during the last quarter. Fisher Asset Management LLC raised its position in Stryker by 2.6% during the fourth quarter. Fisher Asset Management LLC now owns 4,042,317 shares of the medical technology company’s stock worth $1,210,512,000 after acquiring an additional 103,326 shares in the last quarter. Finally, Northern Trust Corp lifted its stake in Stryker by 3.9% in the third quarter. Northern Trust Corp now owns 3,505,595 shares of the medical technology company’s stock valued at $957,974,000 after acquiring an additional 131,590 shares during the last quarter. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

SYK has been the topic of several recent analyst reports. TD Cowen boosted their price objective on shares of Stryker from $365.00 to $400.00 and gave the stock a “buy” rating in a research note on Thursday, April 11th. UBS Group upped their price objective on Stryker from $339.00 to $351.00 and gave the company a “neutral” rating in a research note on Wednesday. BTIG Research lifted their target price on Stryker from $366.00 to $369.00 and gave the stock a “buy” rating in a research note on Wednesday. Canaccord Genuity Group raised Stryker from a “hold” rating to a “buy” rating and set a $360.00 target price on the stock in a report on Wednesday, January 31st. Finally, Canaccord Genuity Group raised Stryker from a “hold” rating to a “buy” rating and raised their price target for the company from $315.00 to $360.00 in a report on Wednesday, January 31st. Four analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $365.94.

Stryker Price Performance

Shares of NYSE SYK traded up $1.82 during midday trading on Friday, reaching $328.45. The company’s stock had a trading volume of 1,589,424 shares, compared to its average volume of 1,415,127. The company has a market cap of $125.12 billion, a P/E ratio of 37.49, a P/E/G ratio of 2.56 and a beta of 0.91. Stryker Co. has a fifty-two week low of $249.98 and a fifty-two week high of $361.41. The company has a debt-to-equity ratio of 0.56, a quick ratio of 0.97 and a current ratio of 1.71. The business’s 50 day moving average price is $346.99 and its two-hundred day moving average price is $317.29.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Tuesday, April 30th. The medical technology company reported $2.50 earnings per share for the quarter, beating the consensus estimate of $2.36 by $0.14. Stryker had a return on equity of 23.05% and a net margin of 16.03%. The firm had revenue of $5.24 billion during the quarter, compared to analysts’ expectations of $5.10 billion. During the same period in the previous year, the firm earned $2.14 EPS. The company’s quarterly revenue was up 9.7% compared to the same quarter last year. On average, analysts forecast that Stryker Co. will post 11.94 EPS for the current fiscal year.

Stryker Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, April 30th. Stockholders of record on Friday, March 29th were issued a dividend of $0.80 per share. This represents a $3.20 dividend on an annualized basis and a dividend yield of 0.97%. The ex-dividend date was Wednesday, March 27th. Stryker’s dividend payout ratio (DPR) is presently 36.53%.

Insider Buying and Selling

In other news, CAO William E. Berry, Jr. sold 7,690 shares of the business’s stock in a transaction on Thursday, March 7th. The stock was sold at an average price of $358.48, for a total transaction of $2,756,711.20. Following the completion of the transaction, the chief accounting officer now owns 3,675 shares of the company’s stock, valued at approximately $1,317,414. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In related news, CAO William E. Berry, Jr. sold 7,690 shares of the company’s stock in a transaction that occurred on Thursday, March 7th. The shares were sold at an average price of $358.48, for a total transaction of $2,756,711.20. Following the completion of the transaction, the chief accounting officer now directly owns 3,675 shares in the company, valued at approximately $1,317,414. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Ronda E. Stryker sold 201,146 shares of the stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $342.90, for a total transaction of $68,972,963.40. Following the completion of the transaction, the director now directly owns 3,755,128 shares of the company’s stock, valued at approximately $1,287,633,391.20. The disclosure for this sale can be found here. 5.90% of the stock is currently owned by company insiders.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.